Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
11,674
archived clinical trials in
Skin Cancer

Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Activation of pDCs at the Tumor and Vaccine Site With a Toll Like Receptor (TLR) Agonist
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)
Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC
Status: Enrolling
Updated:  12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Vaccination of Melanoma Patients With Total or CD25-depleted Peripheral Blood Mononuclear Cell (PBMC)
Vaccination of Chemotherapy Induced Lymphopenic Unresectable Stage III or Stage IV Melanoma Patients Following Reconstitution With Total or CD25-depleted PBMC
Status: Enrolling
Updated: 12/31/1969
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Measuring Real Time Decision-Making About UVR Protection
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Measuring Real Time Decision-Making About Ultraviolet Radiation (UVR) Protection
Measuring Real Time Decision-Making About UVR Protection
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
University of Louisville
mi
from
Louisville, KY
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
University of Louisville
mi
from
Louisville, KY
Click here to add this to my saved trials
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University
mi
from
Philadelphia, PA
Click here to add this to my saved trials
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
LC Bead Embolization Agent With Doxorubicin in the Treatment Liver Metastasis From Melanoma
Transcatheter Arterial Chemoembolization With Doxorubicin-loaded LC Beads in the Treatment of Liver-dominant Metastases in Patients With Stage IV Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
Status: Enrolling
Updated:  12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
A Phase I Study of Intravenous Recombinant Human IL-15 in Adults With Refractory Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
A Phase I Study of Intravenous Recombinant Human IL-15(rhIL-15) in Adults With Metastatic Malignant Melanoma and Metastatic Renal Cell Cancer
Status: Enrolling
Updated: 12/31/1969
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Capecitabine and Lapatinib Ditosylate in Treating Patients With Squamous Cell Cancer of the Head and Neck
A Phase II Study of Capecitabine and Lapatinib in Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Phase II Study of Tesetaxel in Metastatic Melanoma
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Phase II Study of Tesetaxel in Metastatic Melanoma
A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
Adjuvant Therapy for Patients With Primary Uveal Melanoma With Genetic Imbalance
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma
Status: Enrolling
Updated:  12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
A Phase 1 Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma
Status: Enrolling
Updated: 12/31/1969
Abramson Cancer Center of the University of Pennsylvania
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
A Phase II, Single-Arm Study of Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Chao Family Comprehensive Cancer Center
mi
from
Orange, CA
Click here to add this to my saved trials
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients w/ Basal Cell Carcinomas
Pilot Biomarker Trial to Evaluate the Efficacy of Itraconazole in Patients With Basal Cell Carcinomas
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins Medicine
mi
from
Baltimore, MD
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Using High Resolution Function Imaging To Detect Melanoma and Dysplastic Nevi
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated:  12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma
Phase II Trial of High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Metastatic Malignant Melanoma
Status: Enrolling
Updated: 12/31/1969
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Encinitas, CA
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Encinitas, CA
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Washington,
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lincoln, NE
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lincoln, NE
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
A Phase II Open-Label, Multicenter Study of Denileukin Diftitox in Patients With Stage IIIC and Stage IV Melanoma
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Amarillo, TX
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Rose Medical Center
mi
from
Denver, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Swedish Medical Center
mi
from
Englewood, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Poudre Valley Hospital
mi
from
Fort Collins, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
McKee Medical Center
mi
from
Loveland, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
North Suburban Medical Center
mi
from
Thornton, CO
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
North Suburban Medical Center
mi
from
Thornton, CO
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Memorial Hospital
mi
from
Carthage, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates
mi
from
Chicago, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates
mi
from
Chicago, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Mason District Hospital
mi
from
Havana, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Mason District Hospital
mi
from
Havana, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
McDonough District Hospital
mi
from
Macomb, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
McDonough District Hospital
mi
from
Macomb, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
BroMenn Regional Medical Center
mi
from
Normal, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
BroMenn Regional Medical Center
mi
from
Normal, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Proctor Hospital
mi
from
Peoria, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Proctor Hospital
mi
from
Peoria, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Methodist Medical Center of Illinois
mi
from
Peoria, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Illinois CancerCare-Peoria
mi
from
Peoria, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Perry Memorial Hospital
mi
from
Princeton, IL
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Perry Memorial Hospital
mi
from
Princeton, IL
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Mercy Medical Center - Sioux City
mi
from
Sioux City, IA
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Chanute
mi
from
Chanute, KA
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - Dodge City
mi
from
Dodge City, KA
Click here to add this to my saved trials
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated:  12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery
A Phase II Trial of GM-CSF Protein Plus Ipilimumab in Patients With Advanced Melanoma
Status: Enrolling
Updated: 12/31/1969
Cancer Center of Kansas, PA - El Dorado
mi
from
El Dorado, KA
Click here to add this to my saved trials